Heterogeneous clinical presentations characterize systemic lupus erythematosus (SLE), a chronic autoimmune condition with manifestations involving multiple systems. Conventional immunosuppression remains the primary treatment, but it is often ineffective and, as it is toxic, does not prevent the disease from recurring. Biologics, small molecules, and management strategies have altered the algorithm for selecting a treatment for patients. This chapter discusses new approaches to SLE therapy: diagnostic markers, novel therapies, and patient-led care. The diagnosis and monitoring of disease have been enhanced with the newer biomarkers, such as anti-C1q antibodies, the interferon signatures, and complement split products. Biological drugs like belimumab, anifrolumab, and Janus kinase inhibitors seem to effectively reduce disease activity and corticosteroid dependence. A multidisciplinary approach to cardiovascular risk, renal protection, neuropsychiatric complications, vaccination, and psychosocial support has become essential in the prevention of complications and the improvement of outcomes. The next generation of personalized medicine and durable remission is through digital health solutions and precision medicine programs. A new dimension in the treatment of SLE is emerging, shifting from nonspecific immunosuppression to a guided, personalized, mechanistically led approach that includes both general care and targeted therapies. The integration of these biomarkers, new lupus therapeutics, and supportive approaches leads to better control and a more satisfactory quality of lupus life.